ALLMedicine™ Liposarcoma Center

May 19th, 2022 - Monotherapy with eribulin or gemcitabine has been found to be moderately effective in treating soft-tissue sarcomas (STS). In this study, we evaluated the efficacy and safety of eribulin-gemcitabine combination therapy for the two most common hist...

May 18th, 2022 - A man in his 50s was redirected by his general practitioner to our University Hospital for a radiological evaluation after the complaint of a left inguinal swelling. The preliminary ultrasound and CT scan showed a left parafunicolar mass located b...

May 14th, 2022 - No prospective trial with anthracycline-based chemotherapy has individually assessed response in a well-differentiated (WD)/dedifferentiated (DD) liposarcoma patient cohort. We conducted a retrospective analysis of first-line chemotherapy in lipos...

May 14th, 2022 - Soft tissue sarcomas (STSs) are a heterogeneous group of cancers with over 100 described subtypes. While these cancers are infrequent, the prognosis is quite poor, particularly for those with stage IV metastatic disease. Patients for whom curative...

May 13th, 2022 - Hypopharyngeal liposarcoma is an extremely rare entity, and yet fewer than 40 cases have been reported in the literature. Lacking the possibility of distant metastases, local surgical resection with a clear margin can achieve the purpose of treatm...

Apr 29th, 2022 - PRIMARY OBJECTIVES: I. To assess the safety and tolerability of the combination of trabectedin and avelumab in subjects with advanced leiomyosarcoma and liposarcoma. II. To assess the objective response rate of advanced L-type sarcoma patients rec...

Apr 22nd, 2022 - PRIMARY OBJECTIVES: I. To determine progression free rate at week 12 for patients with soft tissue sarcoma (STS) treated with pazopanib (pazopanib hydrochloride) plus oral topotecan (topotecan hydrochloride). SECONDARY OBJECTIVES: I. To determine ...

Apr 20th, 2022 - Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease the outcome is po...

Apr 6th, 2022 - Sarcomas are a group of cancers which arise from connective tissue and bone, of which more than 50 subtypes exist. Approximately 12,000 people are diagnosed with sarcoma annually in the United States. Liposarcoma is one of the more common types of...

Mar 31st, 2022 - The investigators' primary outcome is overall complication rate after treatment with NA H-PBT and surgical resection based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.2 Secondary objectives...

Dec 4th, 2021 - The combination of ribociclib (Kisqali) and everolimus (Afinitor) elicits responses in patients with advanced dedifferentiated liposarcoma (DDLPS) and offers a tolerable safety profile, according to Margaret von Mehren, MD, who added that these re...

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes where patients have limited therapeutic options. ...

Oct 6th, 2021 - George D. Demetri, MD The path of trabectedin (Yondelis), an investigational treatment for soft tissue sarcomas, has been an interesting one, said George D. Demetri, MD, director of the Center for Sarcoma and Bone Oncology at the Dana-Farber Canc...

Oct 6th, 2021 - George D. Demetri, MD Trabectedin demonstrated superior disease control compared with dacarbazine in heavily pretreated patients with advanced soft tissue sarcoma, according to findings from a phase III trial published in the Journal of Clinical ...

Oct 6th, 2021 - Neeta Somaiah, MD Therapeutic advances in soft tissue sarcoma have occurred across several subtypes, and more research efforts continue to be conducted with novel agents targeting NY-ESO-1 and MAGE-A4, for example, explained Neeta Somaiah, MD. F...